Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Matthew Plooster Insider Profile
4 Followers
Matthew Plooster, Director at Zevra Therapeutics, holds 20.10K shares in Zevra Therapeutics (Ticker: ZVRA). Most recently, Matthew Plooster Bought $11,000 shares of Zevra Therapeutics on Mar 13, 2023 for an estimated value of 46.09K.
Profitable Transactions
2 out of 3 Profitable Transactions
Average Return
-8.40%
Average return per transaction
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Matthew Plooster's holdings
Insider Roles
Director
Roles that Matthew Plooster holds in companies
Most Profitable Insider Trade
The most profitable trade made by Matthew Plooster
Matthew Plooster's Trading History
List of latest transactions for each holding click on a transaction to see Matthew Plooster's performance on stock
You May Also Like
Matthew Plooster insider profile FAQ
What is the percentage of profitable transactions made by Matthew Plooster?
The percentage of profitable transactions made by Matthew Plooster is 67%.
What is the average return per transaction made by Matthew Plooster?
The average return per transaction made by Matthew Plooster is -8.40%.
What stocks does Matthew Plooster hold?
Matthew Plooster holds: ZVRA stocks.
What was Matthew Plooster’s latest transaction?
Matthew Plooster latest transaction was an Informative Buy of $46.09K.
What was Matthew Plooster's most profitable transaction?
Matthew Plooster’s most profitable transaction was an Informative Buy of ZVRA stock on March 13, 2023. The return on the trade was 41.40%.
What is Matthew Plooster's role in Zevra Therapeutics?
Matthew Plooster's role in Zevra Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.